The NASA Broad-Specification Fuels Combustion Technology Program: An Assessment of Phase I Test Results

1983 ◽  
Author(s):  
James S. Fear
Keyword(s):  
Adverse Effects ◽  
Phase I ◽  
Phase Ii ◽  
Pollutant Emissions ◽  
Test Results ◽  
Combustion System ◽  
Technology Program ◽  
Advanced Combustion ◽  
Combustion Technology ◽  
Selection Of

An assessment is made of the results of phase I screening testing of current and advanced combustion system concepts using several broadened-properties fuels. The severity of each of several fuels-properties effects on combustor performance or liner life is discussed, as well as design techniques with the potential to offset these adverse effects. The selection of concepts to be pursued in Phase II refinement testing is described. This selection takes into account the relative costs and complexities of the concepts, the current outlook on pollutant emissions control, and practical operational problems.

Cross-Comparison of One-Dimensional Thermal-Hydraulic Codes on Natural Circulation Analysis of NACIE Loop Test for Lead-Alloy Cooled Advanced Nuclear Energy Systems (LACANES)

2014 ◽  
Author(s):  
Yong-Hoon Shin ◽  
Il Soon Hwang ◽  
Massimiliano Polidori ◽  
Paride Meloni ◽  
Vincenzo Casamassima ◽  
...  
Keyword(s):  
Phase I ◽  
Phase Ii ◽  
Nuclear Energy ◽  
Natural Circulation ◽  
Energy Systems ◽  
Research Centre ◽  
Hydraulic Loss ◽  
Lead Alloy ◽  
Test Results ◽  
One Dimensional

As one of the Generation-IV reactor concepts, lead-alloy-cooled advanced nuclear energy systems (LACANES) have been studied worldwide in order to utilize the advantages of good heat transfer properties, neutron transparency and chemical inertness with air and water. Since the Fukushima accident, the passive safety aspect of the LACANES is increasingly emphasized due to outstanding natural circulation capability. To investigate the thermal-hydraulic capability of LBE, an international cooperation has been performed under OECD/NEA program, under the guidance of the Nuclear Science Committee by a task force named as Lead Alloy Cooled Advanced Nuclear Energy Systems (LACANES) since 2007. This international collaboration had dealt with computational benchmarking of isothermal LBE forced convection tests in the phase I, and the working group published a guideline for using one-dimensional system codes to simulate LBE forced circulation test results from HELIOS loop. The phase II was started after that, to give an additional guideline in the case of natural circulation. NACIE, one of benchmarking targets for the phase II which is a rectangular-shape loop located at ENEA-Brasimone Research Centre, Italy. NACIE test results were benchmarked by each participant using their one-dimensional thermal-hydraulic codes, and they are to follow the guideline from the LACANES phase I for regions where hydraulic loss occurs. Due to the selection of hydraulic loss coefficient relations by users, the cross-comparison results of international participants showed some discrepancies and the estimated mass flow rates had 13% of maximum error. Also, the future R&D areas are identified.

Field ladar demonstration (FLD) system, algorithms, and Phase I/Phase II test results

1996 ◽  
Author(s):  
Mark A. Kovacs ◽  
Subrata Ghoshroy ◽  
Victor H. Hasson ◽  
Richard H. Pohle ◽  
Francis J. Corbett ◽  
...  
Keyword(s):  
Phase I ◽  
Phase Ii ◽  
Test Results

Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors

2015 ◽  
Vol 33 (9) ◽  
pp. 1060-1066 ◽  
Author(s):  
Adil I. Daud ◽  
Michelle T. Ashworth ◽  
Jonathan Strosberg ◽  
Jonathan W. Goldman ◽  
David Mendelson ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Phase I ◽  
Phase Ii ◽  
Ex Vivo ◽  
Dose Intensity ◽  
Median Number ◽  
Qtc Prolongation ◽  
Checkpoint Kinase ◽  
Checkpoint Kinase 1 ◽  
Recommended Phase Ii Dose

Purpose We determined the safety, pharmacokinetics, pharmacodynamics, and recommended phase II dose of MK-8776 (SCH 900776), a potent, selective checkpoint kinase 1 (Chk1) inhibitor, as monotherapy and in combination with gemcitabine in a first-in-human phase I clinical trial in patients with advanced solid tumor malignancies. Patients and Methods Forty-three patients were treated by intravenous infusion with MK-8776 at seven dose levels ranging from 10 to 150 mg/m2 as monotherapy and then in combination with gemcitabine 800 mg/m2 (part A, n = 26) or gemcitabine 1,000 mg/m2 (part B, n = 17). Forty percent of patients had three or more prior treatment regimens, and one third of patients had previously received gemcitabine. Results As monotherapy, MK-8776 was well tolerated, with QTc prolongation (19%), nausea (16%), fatigue (14%), and constipation (14%) as the most frequent adverse effects. Combination therapy demonstrated a higher frequency of adverse effects, predominantly fatigue (63%), nausea (44%), decreased appetite (37%), thrombocytopenia (32%), and neutropenia (24%), as well as dose-related, transient QTc prolongation (17%). The median number of doses of MK-8776 administered was five doses, with relative dose-intensity of 0.96. Bioactivity was assessed by γ-H2AX ex vivo assay. Of 30 patients evaluable for response, two showed partial response, and 13 exhibited stable disease. Conclusion MK-8776 was well tolerated as monotherapy and in combination with gemcitabine. Early evidence of clinical efficacy was observed. The recommended phase II dose is MK-8776 200 mg plus gemcitabine 1,000 mg/m2 on days 1 and 8 of a 21-day cycle.

scholarly journals Screening for Coronavirus Disease 2019 (COVID-19) at the Pediatric Emergency Department During Different Pandemic Phases

2021 ◽  
Vol 9 ◽  
Author(s):  
Indrė Stacevičienė ◽  
Sigita Burokienė ◽  
Aušra Steponavičienė ◽  
Daiva Vaičiūnienė ◽  
Roma Puronaitė ◽  
...  
Keyword(s):  
Emergency Department ◽  
Phase I ◽  
Phase Ii ◽  
Wide Spectrum ◽  
Age Groups ◽  
Pediatric Emergency ◽  
Phase Iii ◽  
Pediatric Emergency Department ◽  
Test Results ◽  
History Of

The wide spectrum of COVID-19 symptoms complicates the selection of target groups for screening. We aimed to compare data of children screened for COVID-19 at the pediatric emergency department in Vilnius between different phases throughout 1 year (Phase I: March–May, 2020; Phase II: June–September, 2020; and Phase III: October, 2020–February, 2021) and to evaluate the possible predictors of the disease. SARS-CoV-2 PCR tests were positive for 2.7% of tested children (248/9,238), significantly higher during the Phase III (5.5%) compared with the Phase I (0.6%, p = 0.000) and Phase II (0.3%, p = 0.000). Infants and teenagers (12–17 years) accounted for a larger proportion of COVID-19 patients (24.6 and 26.2%, respectively) compared to other age groups: 1–2 years (18.9%), 3–6 years (14.9%), and 7–11 years (15.3%). There were more COVID-19 cases among children with a known SARS-CoV-2 exposure compared to those who did not declare any contact (18.2 vs. 1.1%, p = 0000). When symptoms were adjusted for age, gender and known exposure to SARS-CoV-2, we found that fever (OR 2.66; 95% CI 1.89–3.81), pharyngitis (OR 1.35; 95% CI 1.01–1.80), headache (OR 1.81; 95% CI 1.09–2.90), and anosmia/ageusia (OR 6.47; 95% CI 1.61–22.47) were the most significant predictors.Conclusion: Although high numbers of testing were maintained throughout the year, the positive test results were significantly higher during the Phase III. Age (<1 year, 12–17 years), a history of exposure to SARS-CoV-2 and some symptoms, such as fever, pharyngitis, headache and anosmia/ageusia could aid in targeting groups for screening for COVID-19 in children.

scholarly journals GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy—study protocol

BMJ Open ◽  
2019 ◽  
Vol 9 (8) ◽  
pp. e026666 ◽  
Author(s):  
David Pasquier ◽  
Marie-Cécile Le Deley ◽  
Emmanuelle Tresch ◽  
Luc Cormier ◽  
Martine Duterque ◽  
...  
Keyword(s):  
Phase I ◽  
Phase Ii ◽  
Local Treatment ◽  
Specific Antigen ◽  
Primary Objective ◽  
Recommended Dose ◽  
Time Interval ◽  
Clinical Progression ◽  
Free Survival ◽  
Selection Of

IntroductionProstate cancer is the third most important cancer in terms of mortality in men. No standard local treatment exists for patients with an intraprostatic recurrence after radiotherapy. Stereotatic body radiotherapy (SBRT) could be a curative treatment for local recurrence. The phase I/II primary objective is the selection of the recommended dose for salvage-SBRT and to estimate the efficacy.Methods and analysisWe plan to perform a multicentre prospective phase I/II study including at least 47 patients. Eligible patients are patients with biochemical recurrence occurring at least 2 years after external radiotherapy for prostatic adenocarcinoma by the Phoenix definition (prostate-specific antigen (PSA) nadir +2 ng/mL) and histologically proven intraprostatic recurrence only (stage T1-T2 on relapse, PSA level ≤10 ng/mL, PSA doubling time >10 months, absence of pelvic or metastatic recurrence proven by choline or PSMA positron emission tomography scan, and pelvic and prostatic assessment by multiparametric MRI). The phase I primary objective is the selection of the recommended dose for salvage-SBRT (5×6, 6×6 or 5×5 Gy) based on dose-limiting toxicity (DLT). The dose of salvage-SBRT will be selected using a time-to-event continual reassessment method based on DLT defined as grade ≥3 gastrointestinal or urinary toxicity or any other grade 4 adverse event. The phase II primary outcome is to estimate the efficacy of the salvage-SBRT in terms of biochemical relapse-free survival rate (Phoenix definition: increase in serum total PSA ≥2 ng/mL above the nadir). Phase II secondary outcomes are acute and late toxicities, quality of life, clinical progression-free survival defined as the time interval between the date of registration and the date of clinical progression or death irrespective of the cause.Ethics and disseminationThe study has received ethical approval from the Ethics committee ‘Ile-de-France III’. Academic dissemination will occur through publication and conference presentations.Trial registration numberNCT03438552

NASA/General Electric Broad-Specification Fuels Combustion Technology Program: Phase I

1983 ◽  
Vol 7 (6) ◽  
pp. 508-517 ◽  
Author(s):  
W. J. Dodds ◽  
E. E. Ekstedt ◽  
D. W. Bahr ◽  
J. S. Fear
Keyword(s):  
Phase I ◽  
General Electric ◽  
Technology Program ◽  
Combustion Technology
Sign in / Sign up

Export Citation Format

Share Document